CF case study: How patients can get costly orphans reimbursed
This article was originally published in Scrip
Companies that want to secure reimbursement for their expensive orphans could learn much from what happened in Ireland with Vertex' cystic fibrosis drug Kalydeco (ivacaftor). When the local health technology assessment recoiled at its €234,000 price tag, patients stepped in to show the National Centre for Pharmacoeconomics the drug's true value.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.